Forum Financial Management LP Sells 3,247 Shares of Stryker Corporation $SYK

Forum Financial Management LP cut its holdings in Stryker Corporation (NYSE:SYK) by 82.2% during the 1st quarter, HoldingsChannel reports. The fund owned 705 shares of the medical technology company’s stock after selling 3,247 shares during the quarter. Forum Financial Management LP’s holdings in Stryker were worth $232,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of SYK. Brown Miller Wealth Management LLC increased its holdings in shares of Stryker by 0.5% during the first quarter. Brown Miller Wealth Management LLC now owns 7,484 shares of the medical technology company’s stock worth $2,459,000 after purchasing an additional 37 shares during the period. EWA LLC acquired a new stake in Stryker during the first quarter worth approximately $215,000. Simmons Bank increased its stake in Stryker by 2.7% during the 1st quarter. Simmons Bank now owns 2,289 shares of the medical technology company’s stock worth $752,000 after acquiring an additional 60 shares during the period. North Star Investment Management Corp. increased its stake in Stryker by 0.4% during the 1st quarter. North Star Investment Management Corp. now owns 8,960 shares of the medical technology company’s stock worth $2,944,000 after acquiring an additional 38 shares during the period. Finally, Continuum Advisory LLC raised its holdings in Stryker by 12.8% in the 1st quarter. Continuum Advisory LLC now owns 1,547 shares of the medical technology company’s stock valued at $508,000 after acquiring an additional 176 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SYK. Needham & Company LLC cut their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Citigroup dropped their price target on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. UBS Group cut their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Finally, Robert W. Baird set a $385.00 target price on shares of Stryker in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $395.33.

Insider Activity

In related news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the transaction, the vice president directly owned 177 shares in the company, valued at $50,170.65. This represents a 95.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Stryker Trading Down 0.5%

Shares of SYK opened at $313.38 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The firm has a market cap of $120.14 billion, a price-to-earnings ratio of 36.27, a PEG ratio of 2.02 and a beta of 0.77. The business’s fifty day moving average is $309.89 and its 200-day moving average is $339.15.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.